Clinical Trials Logo

Clinical Trial Summary

Conventional therapy of upper respiratory tract infection (URTI) is not always effective and sometimes leads to side effects and also to inappropriate use of antibiotic. Hence, a search for safe and effective further treatment options is justified and would be a welcome addition to available conventional treatment. Use of plant based dietary supplements has become increasingly popular over the last few decades or so. Research based on some plants is more than centuries old and its main therapeutic objective is to stimulate the self-healing power of the body. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19. A. Paniculata is a patented extract, standardized to Andrographolide, 14-deoxyandrographolide, and Neo-andrographolide. Maqui contains Maqui Berry Extract of Aristotelia Chilensis (10% Anthocyanidin, 8% Delphinidin) belonging to the family of Elaeocarpaceae, which has been known for its use in several conditions such as sore throat, fever and several other ailments. In the present study, the therapeutic potential of Andrographis Paniculata and Aristotelia chilensis as single ingredients as well as in combination will be evaluated in participants with common cold and COVID related symptoms. The products to be evaluated have been rigorously standardized and are available under the brand names of A. Paniculata and A. Chilensis. Literature indicates that both A. Paniculata and A.Chilensis are effective and safe in the treatment of typical cold-related symptoms in adults.


Clinical Trial Description

The common cold is one of the most frequent minor illnesses in the world. A large US-American survey showed that over 70% of the population annually was suffering from at least one viral respiratory tract infection. Also the economic burden in the USA was almost USD 40 billion annually causing considerable direct and indirect healthcare costs. Caused by 200 identified types of viruses, the common cold is primarily associated with rhinoviruses. Common cold symptoms may include sore throat, runny nose, general malaise, and low-grade fever at onset, followed by nasal congestion and cough. While benign, they last for several days and cause 40% of all missed work days. Complications also include sinusitis, otitis media and pneumonia, exacerbations of asthma and chronic obstructive pulmonary disease, and serious illness in immunocompromised patients. Colds typically afflict most adults and adolescents 2-4 times a year and symptoms usually peak around day 3 or 4 and last 1-2 weeks with a median of 7 days. There is no approved specific therapy for URTI, treatment is therefore mainly symptomatic. The most common pharmacological treatments are antipyretics, anti-inflammatory drugs, expectorants, decongestants, and cough suppressants, either alone or in combination. Supportive measures can include bed rest, hot baths, and inhalations, gargling, and drinking plenty of fluids. Antibiotics are widely prescribed, but often is inappropriate because URTI are mostly caused by viruses and are only indicated in the case of bacterial infection. Its overuse can also lead to the development of community acquired resistant pathogens which are an increasing and serious health burden. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04955327
Study type Interventional
Source Vedic Lifesciences Pvt. Ltd.
Contact
Status Completed
Phase Phase 3
Start date March 20, 2021
Completion date February 25, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06052540 - Probiotic Supplementation in Children Affected by Upper Respiratory Infections N/A
Completed NCT04960878 - The Effect of Synbiotics on the Upper Respiratory Tract Infection N/A
Terminated NCT00979667 - A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Phase 3
Recruiting NCT04479657 - Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection Early Phase 1
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT06065176 - The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection Phase 4
Recruiting NCT01985620 - The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate. N/A
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT00551382 - Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study Phase 3
Completed NCT00393835 - A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis Phase 3
Not yet recruiting NCT05612893 - Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
Completed NCT06149117 - Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China Phase 4
Active, not recruiting NCT05569330 - Effect of Aerosol Filtering on Infectious Diseases in Day Care N/A
Recruiting NCT05374070 - Antiviral Activity of Oral Probiotics N/A
Completed NCT00707941 - Oseltamivir Randomised Controlled Efficacy Trial Phase 3
Completed NCT00858494 - Homeopathic Cold Medicine for Children N/A
Completed NCT01735084 - Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life Phase 4
Not yet recruiting NCT03461692 - A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection(a Chinese Medicine Injection)Used in Hospitals in China N/A
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Recruiting NCT05915390 - Walnut and Immunity Study N/A